Actively Recruiting
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Led by Eli Lilly and Company · Updated on 2026-03-27
128
Participants Needed
9
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.
CONDITIONS
Official Title
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a body mass index (BMI) within the range 18 to 40 kilogram per square meter (kg/m)
You will not qualify if you...
- Have current serious or unstable illnesses affecting major organ systems or a life expectancy under 24 months
- Have hemoglobin less than 12 g/dL or evidence of iron deficiency or hemoglobinopathy
- Are actively suicidal or at significant risk for suicide
- Regularly use drugs of abuse or test positive on drug screening without explanation
- Have previous exposure to any anti-tau therapy
- Are pregnant, intend to become pregnant, or plan to breastfeed during the study
- For Part B: currently exposed to amyloid targeted therapy (exceptions may apply), sensitive to florataucipir 18F, or have MRI contraindications such as claustrophobia or metal implants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States, 90720
Actively Recruiting
2
K2 Medical Research - The Villages
Lady Lake, Florida, United States, 32159
Actively Recruiting
3
K2 Medical Research
Maitland, Florida, United States, 32751
Actively Recruiting
4
Atlanta Center of Medical Research
Atlanta, Georgia, United States, 30331
Actively Recruiting
5
CenExel iResearch, LLC (CenExel iRA)
Decatur, Georgia, United States, 30030
Actively Recruiting
6
CenExel-HRI
Marlton, New Jersey, United States, 08053
Actively Recruiting
7
Duke Early Phase Research Unit
Durham, North Carolina, United States, 27710
Not Yet Recruiting
8
The University of Tokyo Hospital
Bunkyō City, Japan, 113-8654
Not Yet Recruiting
9
National Center for Geriatrics and Gerontology
Ōbu, Japan, 4748511
Not Yet Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here